Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars Opportunity In China, But Regulatory Pathway Still Missing - Biosimilars Asia Conference

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Biosimilars makers foresee a huge opportunity in the emerging pharma market of China, which is expected to grow by 22-25% as of 2014, speakers from the IBC Biosimilars Asia Conference in Shanghai said May 24

You may also be interested in...

Increased Biomarker Testing Could Boost Oncology Market In China

SHANGHAI - China's oncology market is one of the fastest-growing subsectors with cancer now the second-leading cause of death in China. Although the cost of oncology drugs is often prohibitive, increased biomarker testing could help increase access to innovative cancer treatments in China

After Brazil Onto China? Amgen Unveils Emerging Market Strategy

The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say

Sanofi-Aventis Scans Asian Firms For Alliances In Biosimilar Development And Marketing

SINGAPORE - European drug maker Sanofi-Aventis is scouting for Asia-centric joint ventures or collaborative arrangements to accelerate its presence in the biosimilars space. Sanofi is hoping to make up ground as some of its global peers have advanced in the segment to capitalize on some of the biggest revenue drivers expected to unfold in the next five to eight years

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts